Celltrion
Biosimilar developer, South Korea. 10 development products across 10 molecules: adalimumab, aflibercept, bevacizumab, denosumab, infliximab, omalizumab, rituximab, tocilizumab, trastuzumab, ustekinumab.
First approval in the Atlas: Sep 2013, Remsima, infliximab (EMA)
FDAproducts approved10
EMAproducts approved10
PMDAproducts approved8
HCproducts approved10
CDSCOproducts approved1
EDEproducts registered3
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Adalimumab | Yuflyma CT-P17 | May 2023 | Feb 2021 | Sep 2023 | Dec 2021 | · | · |
| Aflibercept | Eydenzelt CT-P42 | Oct 2025 | Feb 2025 | Mar 2026 | Nov 2025 | · | · |
| Bevacizumab | Vegzelma CT-P16 | Sep 2022 | Aug 2022 | Sep 2022 | Jan 2023 | · | · |
| Denosumab | Stoboclo / Osenvelt CT-P41 | Feb 2025 | Feb 2025 | · | Sep 2025 | · | · |
| Infliximab | Remsima / Inflectra CT-P13 | Apr 2016 | Sep 2013 | Jul 2014 | Jan 2014 | Sep 2021 | Jun 2017 |
| Omalizumab | Omlyclo CT-P39 | Mar 2025 | May 2024 | Mar 2026 | Dec 2024 | · | · |
| Rituximab | Truxima / Blitzima CT-P10 | Nov 2018 | Feb 2017 | · | Apr 2019 | · | Apr 2020 |
| Tocilizumab | Avtozma CT-P47 | Jan 2025 | Feb 2025 | Sep 2025 | Oct 2025 | · | · |
| Trastuzumab | Herzuma CT-P6 | Dec 2018 | Feb 2018 | Mar 2018 | Sep 2019 | · | Apr 2020 |
| Ustekinumab | Steqeyma CT-P43 | Dec 2024 | Aug 2024 | Mar 2025 | Jul 2024 | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- EMASep 2013Remsima, infliximab
- HCJan 2014Remdantry, infliximab
- PMDAJul 2014Infliximab BS NK, infliximab
- FDAApr 2016Inflectra, infliximab
- EMAFeb 2017Truxima, rituximab
- EDEJun 2017Remsima, infliximab
- EMAJul 2017Blitzima, rituximab
- EMAFeb 2018Herzuma, trastuzumab
- PMDAMar 2018Trastuzumab BS NK, trastuzumab
- FDANov 2018Truxima, rituximab
- FDADec 2018Herzuma, trastuzumab
- HCApr 2019Truxima, rituximab
- HCSep 2019Herzuma, trastuzumab
- EDEApr 2020Herzuma, trastuzumab
- EDEApr 2020Truxima, rituximab
- HCJan 2021Remsima SC, infliximab
- EMAFeb 2021Yuflyma, adalimumab
- CDSCOSep 2021Pfizer (INN only), infliximab
- HCDec 2021Yuflyma, adalimumab
- EMAAug 2022Vegzelma, bevacizumab
- PMDASep 2022Bevacizumab BS CTNK, bevacizumab
- FDASep 2022Vegzelma, bevacizumab
- HCJan 2023Vegzelma, bevacizumab
- FDAMay 2023Yuflyma, adalimumab
- PMDASep 2023Adalimumab BS CTNK, adalimumab
- EMAMay 2024Omlyclo, omalizumab
- HCJul 2024Steqeyma, ustekinumab
- EMAAug 2024Steqeyma, ustekinumab
- HCDec 2024Omlyclo, omalizumab
- FDADec 2024Steqeyma, ustekinumab
- FDAJan 2025Avtozma, tocilizumab
- EMAFeb 2025Eydenzelt, aflibercept
- EMAFeb 2025Avtozma, tocilizumab
- EMAFeb 2025Osenvelt, denosumab
- EMAFeb 2025Stoboclo, denosumab
- FDAFeb 2025Osenvelt, denosumab
- FDAFeb 2025Stoboclo, denosumab
- FDAMar 2025Omlyclo, omalizumab
- PMDAMar 2025Ustekinumab BS CT, ustekinumab
- HCSep 2025Osenvelt, denosumab
- HCSep 2025Stoboclo, denosumab
- PMDASep 2025Tocilizumab BS CT, tocilizumab
- FDAOct 2025Eydenzelt, aflibercept
- HCOct 2025Avtozma, tocilizumab
- HCNov 2025Eydenzelt, aflibercept
- PMDAMar 2026Aflibercept BS CT, aflibercept
- PMDAMar 2026Omalizumab BS CT, omalizumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.